Alison is currently the Global Program Head for the Rare Disease Development at Sanofi Genzyme. She is responsible for defining the strategic focus of Rare Disease development in collaboration with Head of Commercial. She works closely with external innovation and BD to make review and decide on opportunities to be brought forward for consideration including Bioverativ. In addition, Alison now leads the acid sphingomyelinase deficiency (ASMD) (formerly known as Niemann-Pick) Global Team. She coordinates the regulatory, clinical operations, medical affairs, legal and CMC to allow submission for the first in class therapy for this ultra-rare diseases with high mortality and morbidity and no known treatment.
Alison completed her Internal Medicine residency at the Johns Hopkins Hospital and her Cardiology fellowship at Massachusetts General Hospital with a research fellowship at Mount Sinai. She also co-founded the Women’s CARE (Cardiac Assessment and Risk Evaluation) Program to educate and treat under-served women in Spanish Harlem, NY and has appeared on national, local TV and radio as a medical expert on cardiovascular and women’s health.